Optimizing safety of cisplatin treatment Utilizing pharmacogenomics to prevent nephrotoxicity

Personalized cisplatin therapy could be of great potential to minimize the risk of side effects, especially nephrotoxicity without compromising its antineoplastic effect. It remains unclear if genetic factors can predict the risk of nephrotoxicity among cisplatin users. The primary objective of this thesis is to identify and validate genetic variants that could assist the prevention and management of cisplatin-induced nephrotoxicity through candidate gene studies and GWAS. The secondary objective is to identify strategies to minimize cisplatin-induced nephrotoxicity through modification of cisplatin dosing and optimization of co-medication selection. Part 1 of the thesis addresses the impact of genetic variations on cisplatin nephrotoxicity. The studies demonstrate that genetic predisposition could be important in the development of cisplatin-induced nephrotoxicity. These results warrant further replication effort, functional and pharmacokinetic/dynamic validation to reveal the mechanistic basis on how genetic variants may involve in cisplatin-induced nephrotoxicity. In the future, comprehensive assessment on cisplatin toxicities combined with an integration of cisplatin’s systems pharmacology and multi-omics cancer analysis could pave promising opportunities for individualized platinum selection and targeted organ protection including kidney. Part 2 explores the possibility of stratification and modification of cisplatin therapy to minimize nephrotoxicity without compromising its effectiveness. Modification of cisplatin dose and intensity, as well as optimization of standard co-medication such as 5-HT₃ receptor antagonist antiemetics, could potentially minimize the risk of cisplatin-induced kidney injury without waiving its effectiveness. Further evidence from controlled trials and observational studies will strengthen the body of evidence to assess such potentially affordable prevention of cisplatin-induced nephrotoxicity.